Staying attuned to therapeutic nuances—and your goals

Expert medical scientists, tailored processes and project teams

If speed, precision, and quality rank high in your priorities, consider i3’s specialized approach: we tailor our processes and teams to meet the precise demands of your project and therapeutic category. This allows us to provide scientific insight of depth and value.

From common diagnoses such as diabetes and kidney disease to rarer illnesses, each condition examined in endocrinology and metabolic research demands specialized expertise. That is why we build your project team with precision and deliberation.

On every functional level, i3 professionals deliver scientific discipline, expertise, and dedication, making available to your development program an unmatched breadth and depth of knowledge.

Rich resources for in-depth scientific insights

i3 brings extensive resources to this critical research area:

  • Our therapeutic leads offer strategic thinking and stay involved at a high level of medical and scientific oversight throughout study execution
  • Our medical staff includes several board-certified endocrinologists and a doctoral-level bionutritionist
  • Our clinical research experience includes Phases I–IV, INDs, clinical study reports, clinical development plans, pharmacoeconomic studies, epidemiology, and quality-of-life validation
  • Our endocrinology expertise is amplified by the experience of our clinical staff, including project managers, monitors, and advisors

As one of the leading therapeutic categories for clinical drug development, endocrinology and metabolic diseases research is strategically important to i3—you’ll find our teams well-represented.

Our seamless integration of scientific, medical, and operations teams—combined with a unique eye on the therapeutic nuances—means every aspect of your study can be more efficient and exact.

Why i3?

Our experience spans a range of services in this diverse therapeutic category, including more than 65 studies ranging from niche studies in rare diseases to late-phase studies in more than 48,000 patients. We have provided specialized services that include feasibility planning and protocol development, clinical monitoring, regulatory consulting, complete data management, and biostatistics—all on a global scale.